Clinical Trials Browser

Phase 2 × tislelizumab × Head & Neck × Clear all

NCT07601737 2026-05-22

Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally Advanced Head and Neck Squamous Cell Carcinoma

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT07040956 2026-05-04

A Clinical Trial Comparing Low-Dose RT + Targeted Therapy+ Immunotherapy vs Targeted Therapy+ Immunotherapy Alone as Neoadjuvant Therapy in Operable HNSCC Patients.

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT07388758 2026-02-05

Scipibaimab Combined With Tislelizumab in Patients With First-Line Treatment-Failed Recurrent/Metastatic Nasopharyngeal Carcinoma

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT07331428 2026-01-09

MRG003 Induction and Capecitabine Maintenance With PD-1 in Locally Recurrent NPC

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT06804850 2025-11-19

Neoadjuvant Radiotherapy Plus Targeted Therapy and Immunotherapy vs. Targeted Therapy Plus Immunotherapy in Resectable HNSCC

Phase 2 Withdrawn

Head and Neck Neoplasms

NCT05909904 2025-10-07

A Study of Tislelizumab in Combination With Investigational Agents in Participants With Head and Neck Squamous Cell Carcinoma

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT05758389 2025-09-05

Tislelizumab Combined APF Chemotherapy in the Treatment of Locally Advanced Head and Neck Tumors

Phase 2 Recruiting

Head and Neck Neoplasms

NCT05517330 2025-07-31

neoCHANCE-1

Phase 2 Completed

Head and Neck Neoplasms

NCT06009861 2025-06-06

Neoadjuvant Tislelizumab Plus Chemotherapy for Locally Advanced Oral/Oropharyngeal Cancer (NeoSPOT)

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT05516589 2025-05-22

neoCHANCE-2

Phase 2 Completed

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06673693 2025-04-16

NEOSTART

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT04802876 2025-03-21

ACROPOLI

Phase 2 Active not recruiting

BreastDermatologicGastrointestinalGenitourinaryGynecologicHead & NeckOther solid neoplasmSarcomaThoracic

Adenocarcinoma Of Esophagus, Adenocarcinoma of Lung, Squamous Cell Carcinoma of Head and Neck, Carcinoma, Ovarian Epithelial, Uveal Melanoma, Anus Neoplasms, Carcinoma, Renal Cell, Carcinoma, Transitional Cell, Uterine Cervical Neoplasms, Carcinoma, Hepatocellular, Melanoma, Mesothelioma, Neoplasms, Unknown Primary, Sarcoma, Thyroid Neoplasms, Cholangiocarcinoma, Small Cell Lung Carcinoma, Triple Negative Breast Neoplasms

NCT06781112 2025-01-17

A Phase II Study of TPF With PD-1 Inhibitor Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT06728618 2024-12-11

OSCC

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck

NCT05724329 2024-09-19

Neoadjuvant Tislelizumab in Combination With Dasatinib and Quercetin in Resectable HNSCC (COIS-01)

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck

NCT06554028 2024-08-14

Tislelizumab and Induction Chemotherapy for Larynx Preservation in Resectable Advanced Laryngeal/Hypopharyngeal Cancer

Phase 2 Not yet recruiting

Hypopharyngeal Neoplasms, Laryngeal Neoplasms

NCT06366945 2024-04-16

Tirelizumab in Combination With Carboplatin and Polymeric Micellar Paclitaxel for Neoadjuvant Therapy in cN+ HNSCC

Phase 2 Not yet recruiting

Squamous Cell Carcinoma of Head and Neck, Head and Neck Neoplasms

NCT06331845 2024-03-26

Stop and go Strategy as First-line Treatment for Widely Metastatic Nasopharyngeal Carcinoma

Phase 2 Not yet recruiting

Nasopharyngeal Carcinoma

NCT06235918 2024-02-01

Neoadjuvant Tislelizumab Plus Chemotherapy for Resectable Locally-advanced Head and Neck Squamous Cell Carcinoma

Phase 2 Unknown

Squamous Cell Carcinoma of Head and Neck

NCT05862168 2023-07-17

Neoadjuvant Treatment of Tislelizumab Combined Chemotherapy for Locally Advanced Oral Squamous Cell Carcinoma ：A Single-arm, Prospective, Phase II Trial

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT05343325 2022-12-29

The Efficacy and Safety of Neoadjuvant Low-dose Radiotherapy Combined With Chemoimmunotherapy in Locally Advanced HNSCC

Phase 2 Recruiting

Squamous Cell Carcinoma of Head and Neck

NCT05659186 2022-12-21

PD-1 Inhibitor and Anlotinib Combined With Multimodal Radiotherapy in Recurrent or Metastatic Anaplastic Thyroid Cancer

Phase 2 Unknown

Thyroid Neoplasms

NCT05595590 2022-10-27

Radiotherapy With Tislelizumab in Patients With Recurrent Head & Neck Cancer

Phase 2 Recruiting

Head and Neck Neoplasms

NCT05448885 2022-07-08

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

Phase 2 Unknown

Nasopharyngeal Carcinoma

NCT04921995 2022-04-04

RETICULA-NPC

Phase 2 Unknown

Nasopharyngeal Carcinoma

NCT04814069 2021-03-24

A Multicenter Phase II Trial of Post-operative Concurrent Chemoradiotherapy Using Weekly Cisplatin With Tislelizumab for Patients With High-risk Head and Neck Squamous Cell Carcinoma：The POTENTIAL Study

Phase 2 Unknown

Head and Neck Neoplasms